David M. Nanus
Division of Hematology and Medical Oncology
Department of Medicine
Weill Cornell Medical College
New York
USA
Name/email consistency: high
- 2-weekly versus 3-weekly docetaxel for prostate cancer. Nanus, D.M., Tagawa, S.T. Lancet Oncol. (2013)
- Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Nanus, D.M., Garino, A., Milowsky, M.I., Larkin, M., Dutcher, J.P. Cancer (2004)
- Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. Nanus, D.M., Milowsky, M.I., Kostakoglu, L., Smith-Jones, P.M., Vallabahajosula, S., Goldsmith, S.J., Bander, N.H. J. Urol. (2003)
- Interaction of retinoic acid and interferon in renal cancer cell lines. Nanus, D.M., Geng, Y., Shen, R., Lai, H.K., Pfeffer, S.R., Pfeffer, L.M. J. Interferon Cytokine Res. (2000)